Prestige Consumer Healthcare PBH North American OTC Healthcare — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prestige Consumer Healthcare in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prestige Consumer Healthcare's north american otc healthcare — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prestige Consumer Healthcare's north american OTC healthcare — gross profit?
- Prestige Consumer Healthcare (PBH) reported north american OTC healthcare — gross profit of $121.37M in Q1 2026.
- How has Prestige Consumer Healthcare's north american OTC healthcare — gross profit changed year-over-year?
- Prestige Consumer Healthcare's north american OTC healthcare — gross profit decreased by 14.2% year-over-year, from $141.49M to $121.37M.
- What is the long-term trend for Prestige Consumer Healthcare's north american OTC healthcare — gross profit?
- Over 4 years (2022 to 2026), Prestige Consumer Healthcare's north american OTC healthcare — gross profit has grown at a -2.3% compound annual growth rate (CAGR), from $548.72M to $500.88M.
- What does north american OTC healthcare — gross profit mean?
- Calculated as total segment revenue minus the direct cost of sales for North American OTC healthcare operations. It serves as a primary indicator of the segment's ability to price its products effectively while managing manufacturing and supply chain costs. A stable or expanding gross profit margin reflects strong brand equity and pricing power in the consumer health sector.